Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PioSpiMet versus ethinyl estradiol + levonorgestrel in adolescents with ovarian hyperandrogenism and hyperinsulinemia
2012-004100-35Phase 3Completed
- Sponsor
- Fundació Sant Joan de Déu
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pioglitazone, spironolactone, metformin, ethinyl estradiol and avatrombopag in Hyperandrogenism and hyperinsulinemia (2 arms), sponsored by Fundació Sant Joan de Déu. Primary endpoints: Basal insulin, Insulin sensitivity (HOMA) and 4 more. Started Oct 2012; status: completed.
02
Drugs
pioglitazonespironolactonemetforminethinyl estradiolavatrombopag
03
Conditions
Hyperandrogenismhyperinsulinemia
Beyond the preview
Go deeper on 2012-004100-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004100-35.